Last reviewed · How we verify

ROVALCYTE — Competitive Intelligence Brief

ROVALCYTE (ROVALCYTE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous T-cell therapy. Area: Oncology.

phase 3 Autologous T-cell therapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ROVALCYTE (ROVALCYTE) — University Hospital, Rouen. ROVALCYTE is an autologous T-cell therapy that expands and reinfuses a patient's own T cells to enhance anti-tumor immune response.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ROVALCYTE TARGET ROVALCYTE University Hospital, Rouen phase 3 Autologous T-cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous T-cell therapy class)

  1. University Hospital, Rouen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ROVALCYTE — Competitive Intelligence Brief. https://druglandscape.com/ci/rovalcyte. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: